Dr. Harper discusses results from head-to-head studies comparing new and existing oral rosacea treatments and navigating the difficulties of treating neurogenic rosacea.
Dr. Harper discusses results from head-to-head studies comparing new and existing oral rosacea treatments and navigating the difficulties of treating neurogenic rosacea.
Dr. Lio discusses the complex relationship between diet and **Atopic Dermatitis (AD), addressing common patient questions, misconceptions, and concerns regarding dietary modifications. His presentation emphasizes
Dr. Graber reviews emerging evidence supporting the use of energy-based devices for the treatment of Acne Vulgaris and Rosacea, highlighting how advances in laser and
Dr. Daveluy discusses practical techniques and clinical considerations for using cryoinsufflation in the treatment of Hidradenitis Suppurativa (HS). His presentation provides guidance on incorporating this
Dr. Bunick examines the ongoing discussion surrounding benzene contamination concerns in benzoyl peroxide (BPO) products, addressing questions about product safety, regulatory oversight, and best practices
Dr. Swanson highlights key developments presented at the AAD 2025 Annual Meeting, providing an overview of emerging therapies, clinical research, and treatment advances across several
Dr. Lio discusses strategies for addressing chronic itch (pruritus) in patients undergoing treatment for non-dermatologic cancers, a symptom that can significantly affect comfort, sleep quality,
The AAD © Brand and Content are created by the American Academy of Dermatology “All rights reserved.” Any reproduction or republication is strictly prohibited without prior authorization.
The content of the 2025 AAD Innovation Academy Meeting (the “Content”) is copyrighted by the American Academy of Dermatology (“AAD”). The Works, JCADTV Coverage from the 2025 AAD Innovation Academy Meeting, are made up of coverage interviews and summaries and are created from the Content of the AAD under a license between the AAD and Matrix Medical Communications (“MATRIX MEDICAL COMMUNICATIONS”), and MATRIX MEDICAL COMMUNICATIONS is solely responsible for their content. The license of any content by the AAD does not constitute or imply endorsement of any company or its goods, services, or written work products, and the AAD is not responsible for any errors or omissions in the translation or reproduction of the content.
